Adverse events in the treatment of patients with pulmonary tuberculosis combined with diabetes mellitus and without it

<b>Aim:</b> to study the frequency and type of adverse events in the treatment of patients with pulmonary tuberculosis (TB) combined with diabetes mellitus (DM) and without it. <b>Materials and methods:</b> 396 patients with pulmonary TB were examined: 203 patients with pulmonary TB combined with DM and 193 patients with pulmonary TB without DM. <b>The results:</b> It was found that in the group of patients with DM, adverse events (AE) was observed in 71,9% patients. However, in-group of patients without DM, AE was detected in 32,1% of patients (p &lt;0,01). In patients with DM, hepatotoxic reactions occurred significantly more often than in patients without DM (55,2% and 27,4%; p &lt;0,01). The second place in both groups in frequency was occupied by allergic reactions, which were significantly more often observed in the group of patients with DM (20,7% and 6,2%; p &lt;0,01). In the group of patients with pulmonary TB combined with DM, most often, AE was observed on pyrazinamide (65,0%), cycloserine (57,1%) and aminoglycosides (56,4%). In the comparison group, most often, AE detected on protionamide (55,0%) and pyrazinamide (45,6%). Cancellation of the drug and its substitution with another during treatment in the group of patients with pulmonary TB combined with DM was carried out in 41,7% of patients with AE. In the comparison group of such patients, were 27,4% (p &lt;0.02). Aminoglycosides were significantly more often withdrawn in patients with pulmonary TB combined with DM, compared with patients without diabetes (28,2% and 8,6; p &lt;0,05). <b>Conclusion:</b> Adverse events in the treatment of patients with pulmonary TB combined with DM were observed more often compared with TB patients without it<b>.</b>